Clinical Study of Hospital-manufactured CD19 CAR-T in Children and Adolescents With Acute Lymphoblastic Leukemia

This study is testing a CAR-T cell therapy — a treatment where your own immune cells are genetically modified to hunt and kill leukemia cells — for children and young adults with acute lymphoblastic leukemia (ALL) that has come back or did not respond to standard treatment. The CAR-T cells are made at the hospital specifically targeting a marker called CD19 on leukemia cells. **You may be eligible if...** - You are younger than 26 years old - You have CD19-positive ALL that has relapsed (come back) or did not respond to chemotherapy - You have experienced a second or later bone marrow relapse, relapse after a stem cell transplant, or cannot receive a stem cell transplant - You are in a reasonable physical condition (Karnofsky/Lansky score of at least 50) **You may NOT be eligible if...** - You have uncontrolled hepatitis B or C - You have a known HIV infection - You have an active, uncontrolled infection - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.